IL-18 PROMOTER POLYMORPHISM AND IL-18 SERUM LEVELS IN ASSOCIATION WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

IL-18 PROMOTER POLYMORPHISM AND IL-18 SERUM LEVELS IN ASSOCIATION WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

Purpose: Multiple sclerosis is the immune-mediated disorder whose etiology is not completely understood. The present study aimed to survey association between the promoter polymorphism IL18 -607C/A (rs1946518), the serum concentration of IL-18 and susceptibility to relapsing-remitting multiple scler...

Full description

Bibliographic Details
Main Authors:	Boncho Grigorov, Anastasiya Trenova, Antonia Grigorova, Spaska Stanilova
Format:	Article
Language:	English
Published:	Peytchinski Publishing 2020-12-01
Series:	Journal of IMAB
Subjects:	relapsing-remitting multiple sclerosis cytokine rs1946518 snp
Online Access:	https://www.journal-imab-bg.org/issues-2020/issue4/2020vol26-issue4-3475-3480.pdf

Similar Items

A link between promoter polymorphisms of the transforming growth factor β1 (TGFB1) and TGF-β1 receptor II (TGFBR2) genes and relapsing-remitting multiple sclerosis
by: Antonia Grigorova, et al.
Published: (2021-01-01)

Development and Validation of Fear of Relapse Scale for Relapsing-Remitting Multiple Sclerosis: Understanding Stressors in Patients
by: Ali Khatibi, et al.
Published: (2020-03-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

VITAMIN D INTOXICATION IN A PATIENT WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS – CASE REPORT
by: Ioana Cociasu, et al.
Published: (2015-09-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
by: Romme Christensen Jeppe, et al.
Published: (2012-09-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Investigation of oxidative stress in relapse and remission periods of patients with relapsing-Remitting multiple sclerosis
by: Samet Oncel, et al.
Published: (2021-01-01)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017-07-01)

Diffusion tensor imaging of thalamus in relapsing⁃remitting multiple sclerosis patients
by: Yun⁃yun DUAN, et al.
Published: (2012-04-01)

Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis
by: David Haschka, et al.
Published: (2020-04-01)

Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
by: King Man Wan, et al.
Published: (2019-01-01)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
by: Oliver Findling, et al.
Published: (2018-08-01)

[Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]
by: Lorenzo Giovanni Mantovani, et al.
Published: (2017-12-01)

Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis
by: Kira Groen, et al.
Published: (2018-05-01)

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
by: Raed Alroughani, et al.
Published: (2021-01-01)

Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Xin Wu, et al.
Published: (2021-05-01)

The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model
by: Gabriele Di Sante, et al.
Published: (2020-03-01)

Intrinsic functional plasticity of the thalamocortical system in minimally disabled patients with relapsing-remitting multiple sclerosis
by: Fuqing eZhou, et al.
Published: (2016-01-01)

Cortical Excitability and Interhemispheric Connectivity in Early Relapsing–Remitting Multiple Sclerosis Studied With TMS-EEG
by: Carl M. Zipser, et al.
Published: (2018-06-01)

Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data
by: Jacqueline A. Nicholas, et al.
Published: (2019-10-01)

The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis
by: Mohammad Z.I. Asha, et al.
Published: (2021-12-01)

Comparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis
by: Mohammad Reza Gheini, et al.
Published: (2019-11-01)

Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
by: Silvia Boullosa-Lale, et al.
Published: (2021-03-01)

Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase
by: Zbyšek Pavelek, et al.
Published: (2020-05-01)

Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
by: Duygu Tap, et al.
Published: (2020-12-01)

Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
by: Masoud Etemadifar, et al.
Published: (2011-01-01)

Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
by: Lorenzo Giovanni Mantovani, et al.
Published: (2019-07-01)

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment
by: Kumar J, et al.
Published: (2021-07-01)

The Core of Gut Life: <i>Firmicutes</i> Profile in Patients with Relapsing-Remitting Multiple Sclerosis
by: Madina Kozhieva, et al.
Published: (2021-01-01)

Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
by: Mohamed AlJumah, et al.
Published: (2020-02-01)

A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients
by: Gugliandolo A, et al.
Published: (2018-09-01)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
by: Marina Boziki, et al.
Published: (2021-08-01)

Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta
by: Leila Karimi, et al.
Published: (2020-08-01)

Evaluating sex hormones and cytokine profile in Egyptian females with relapsing-remitting multiple sclerosis
by: Forayssa M. Talaat, et al.
Published: (2018-11-01)

A COMPARATIVE ANALYSIS OF EFFICACY OF INTERFERON BETA 1-B AND NATALIZUMAB TREATMENT IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: T. I. Yakushina, et al.
Published: (2016-07-01)

Differential disease phenotypes and progression in relapsing–remitting multiple sclerosis: comparative analyses of single Canadian and Saudi Arabian clinics
by: M. Alluqmani, et al.
Published: (2021-07-01)

Altered intra- and interregional synchronization in relapsing–remitting multiple sclerosis: a resting-state fMRI study
by: Wu L, et al.
Published: (2016-04-01)

Stochastic models for MRI lesion count sequences from patients with relapsing remitting multiple sclerosis
by: Li, Xiaobai
Published: (2006)